Tricida to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Tricida, Inc. (Nasdaq: TCDA) announced its participation in the H.C.

Rhea-AI Summary

Tricida, Inc. (Nasdaq: TCDA) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021. The presentation will provide an overview and update on the company's key initiatives and will be available on their website at 4:00 am PT / 7:00 am ET. An archived version will be accessible for 90 days. Tricida focuses on the development of veverimer, a drug candidate aimed at slowing chronic kidney disease progression in patients with metabolic acidosis, a condition affecting around three million CKD patients in the U.S.

Argus Session date unavailable

-2.36% session move Open Argus

Details

News Market Reaction – TCDA

The recorded move for TCDA in the trading session of this news was -2.36%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference. Tricida will provide a company overview, business update and progress on the company’s key initiatives.

The presentation will be accessible on the Tricida website at IR.Tricida.com on Monday, September 13, 2021 at 4:00 am PT / 7:00 am ET. An archive of the presentation will be available for 90 days following the presentation.

About Tricida

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow chronic kidney disease (CKD) progression in patients with metabolic acidosis and CKD. Tricida is currently conducting a renal outcomes clinical trial, VALOR-CKD, to determine if veverimer slows CKD progression in patients with metabolic acidosis and CKD. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately three million patients with CKD in the United States. There are currently no therapies approved by the FDA to slow progression of kidney disease by correcting metabolic acidosis in patients with CKD.

For more information about Tricida, please visit Tricida.com.

Contact:
Jackie Cossmon
Tricida, Inc.
Senior Vice President of Investor Relations and Communications
IR@Tricida.com

Source: Tricida, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Tricida present at the H.C. Wainwright conference?

Tricida, Inc. will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 4:00 am PT / 7:00 am ET.

How can I access Tricida's presentation?

The presentation will be available on Tricida's website at IR.Tricida.com.

What is the focus of Tricida's drug development?

Tricida is focused on developing veverimer, a drug aimed at slowing the progression of chronic kidney disease in patients with metabolic acidosis.

What clinical trial is Tricida conducting for veverimer?

Tricida is conducting the VALOR-CKD clinical trial to assess if veverimer slows the progression of chronic kidney disease.

How many patients in the U.S. are affected by metabolic acidosis related to CKD?

It is estimated that approximately three million patients in the U.S. are affected by metabolic acidosis due to chronic kidney disease.